Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Zimmer Biomet (ZBH)
NYSEHealth CareMedical - DevicesSnapshot 2026-11-04
$110.15+13.49%
Close 2026-11-04 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
9.07 → 9.06 EPS · FY ending Dec 31, 2027 · 17 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 16 to 17; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for ZBH yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Adjusted EPS of $8.40 to $8.55 in 2026 | Adjusted EPS is raised to about $8.47 per share. | Intact | Adjusted EPS falls below $8.40 in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
ZBH is a healthcare business with a multi-year thesis grounded in earnings quality, recent financial strength, and sector support. Its current thesis state is intact, though the signal has softened from favorable to mildly favorable and management execution is a source of uncertainty.
The valuation evidence is mixed: ZBH is described as cheap versus peers, but its peer premium is also elevated, and overall value is rated neutral. The market’s expectations are tagged as justified, with no identified fragility; the expectations gap is negative, though the evidence does not explain its scale.
Near term, current results and management priorities point to continued revenue growth and delivery on 2026 adjusted EPS guidance. Guidance has been raised, and share repurchases are on track, but a guidance cut would be a meaningful negative; the stated miss risk is low. The recent president transition and volatile management rating add uncertainty.
The multi-year view hinges on maintaining revenue and earnings execution while meeting the raised 2026 guidance. A weakening jobs trend could increase recession concerns for cyclical businesses, while continued strong results and higher guidance from healthcare peers would support the sector backdrop.
For the next 1 to 3 years, ZBH’s long-term thesis remains intact, but its mildly favorable signal and mixed valuation evidence leave execution and the economic backdrop as key swing factors. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| The company plans to repurchase up to $1 billion of shares in 2026. |
| Intact |
| Repurchases fall significantly short of $1 billion in FY26 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth of 2.5% to 4.5% in 2026 | A primary condition in Zimmer Biomet's published investment case. The stated target is 2.5% to 4.5% YoY. | Intact | YoY revenue growth falls below 2.5% in FY26 | Revenue growth: 3.07% FY2026-Q3; GAAP. Published target: 2.5% to 4.5% YoY. Annual target cannot be compared with a quarterly or TTM observation. Nov 4, 20263.072849 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$9.01 → $9.06 · observed estimates
$8.85B → $8.90B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $9.01 | $8,847,744,512 | 16 / 19 |
| 2026-07-25 | $9.00 | $8,842,909,150 | 26 / 25 |
| 2026-07-26 | $9.01 | $8,847,744,512 | 16 / 19 |
| 2026-07-27 | $9.00 | $8,842,909,150 | 26 / 25 |
| 2026-07-28 | $9.01 | $8,847,744,512 | 16 / 19 |
| 2026-07-29 | $9.01 | $8,849,993,944 | 16 / 20 |
| 2026-07-30 | $9.00 | $8,845,171,520 | 27 / 26 |
| 2026-07-31 | $9.01 | $8,849,993,944 | 16 / 20 |
| 2026-08-01 | $9.01 | $8,849,993,944 | 16 / 20 |
| 2026-08-02 | $9.01 | $8,849,993,944 | 16 / 20 |
| 2026-08-03 | $9.00 | $8,845,171,520 | 27 / 26 |
| 2026-08-04 | $9.01 | $8,849,993,944 | 16 / 20 |
| 2026-08-05 | $9.01 | $8,849,993,944 | 16 / 20 |
| 2026-08-06 | $9.01 | $8,849,993,944 | 16 / 20 |
| 2026-08-08 | $9.07 | $8,903,153,310 | 27 / 26 |
| 2026-08-09 | $9.07 | $8,908,141,044 | 16 / 20 |
| 2026-08-10 | $9.07 | $8,904,683,170 | 27 / 26 |
| 2026-08-12 | $9.07 | $8,908,141,044 | 16 / 20 |
| 2026-08-13 | $9.07 | $8,908,141,044 | 16 / 20 |
| 2026-08-14 | $9.07 | $8,908,141,044 | 16 / 20 |
| 2026-08-15 | $9.07 | $8,908,141,044 | 16 / 20 |
| 2026-08-16 | $9.07 | $8,908,141,044 | 16 / 20 |
| 2026-08-17 | $9.07 | $8,908,141,044 | 16 / 20 |
| 2026-08-18 | $9.07 | $8,908,141,044 | 16 / 20 |
| 2026-08-19 | $9.07 | $8,908,141,044 | 16 / 20 |
| 2026-08-20 | $9.07 | $8,909,752,384 | 16 / 20 |
| 2026-08-21 | $9.07 | $8,909,752,612 | 16 / 20 |
| 2026-08-22 | $9.07 | $8,909,752,612 | 16 / 20 |
| 2026-08-23 | $9.07 | $8,909,752,612 | 16 / 20 |
| 2026-08-24 | $9.07 | $8,909,752,612 | 16 / 20 |
| 2026-08-25 | $9.07 | $8,909,752,612 | 16 / 20 |
| 2026-08-26 | $9.07 | $8,909,752,612 | 16 / 20 |
| 2026-08-27 | $9.07 | $8,909,752,612 | 16 / 20 |
| 2026-08-28 | $9.07 | $8,909,752,612 | 16 / 20 |
| 2026-08-29 | $9.07 | $8,909,755,228 | 16 / 20 |
| 2026-08-30 | $9.07 | $8,909,755,228 | 16 / 20 |
| 2026-08-31 | $9.07 | $8,909,755,228 | 16 / 20 |
| 2026-09-01 | $9.07 | $8,909,755,228 | 16 / 20 |
| 2026-09-02 | $9.07 | $8,909,755,228 | 16 / 20 |
| 2026-09-03 | $9.07 | $8,909,755,228 | 16 / 20 |
| 2026-09-04 | $9.07 | $8,909,755,228 | 16 / 20 |
| 2026-09-05 | $9.07 | $8,909,755,228 | 16 / 20 |
| 2026-09-06 | $9.07 | $8,909,755,228 | 16 / 20 |
| 2026-09-07 | $9.07 | $8,909,755,228 | 16 / 20 |
| 2026-09-08 | $9.07 | $8,909,755,228 | 16 / 20 |
| 2026-09-09 | $9.07 | $8,909,755,228 | 16 / 20 |
| 2026-09-10 | $9.07 | $8,909,755,228 | 16 / 20 |
| 2026-09-11 | $9.07 | $8,909,755,228 | 16 / 20 |
| 2026-09-12 | $9.07 | $8,909,755,228 | 16 / 20 |
| 2026-09-13 | $9.07 | $8,909,755,228 | 16 / 20 |
| 2026-09-14 | $9.07 | $8,909,755,228 | 16 / 20 |
| 2026-09-15 | $9.07 | $8,909,755,228 | 16 / 20 |
| 2026-09-16 | $9.07 | $8,909,752,612 | 16 / 20 |
| 2026-09-17 | $9.07 | $8,909,752,612 | 16 / 20 |
| 2026-09-18 | $9.07 | $8,909,752,612 | 16 / 20 |
| 2026-09-19 | $9.07 | $8,909,752,612 | 16 / 20 |
| 2026-09-20 | $9.07 | $8,909,752,612 | 16 / 20 |
| 2026-09-21 | $9.07 | $8,909,752,612 | 16 / 20 |
| 2026-09-22 | $9.07 | $8,909,752,612 | 16 / 20 |
| 2026-09-23 | $9.07 | $8,909,752,612 | 16 / 20 |
| 2026-09-24 | $9.07 | $8,909,752,612 | 16 / 20 |
| 2026-09-25 | $9.07 | $8,909,752,612 | 16 / 20 |
| 2026-09-26 | $9.07 | $8,909,752,612 | 16 / 20 |
| 2026-09-27 | $9.07 | $8,909,752,612 | 16 / 20 |
| 2026-09-28 | $9.07 | $8,909,752,612 | 16 / 20 |
| 2026-09-29 | $9.07 | $8,909,734,156 | 16 / 20 |
| 2026-09-30 | $9.07 | $8,909,734,156 | 16 / 20 |
| 2026-10-01 | $9.07 | $8,909,734,156 | 16 / 20 |
| 2026-10-02 | $9.07 | $8,909,494,156 | 16 / 20 |
| 2026-10-03 | $9.07 | $8,909,494,156 | 16 / 20 |
| 2026-10-04 | $9.07 | $8,909,494,156 | 16 / 20 |
| 2026-10-05 | $9.07 | $8,909,494,156 | 16 / 20 |
| 2026-10-06 | $9.07 | $8,909,494,156 | 16 / 20 |
| 2026-10-07 | $9.07 | $8,909,494,156 | 16 / 20 |
| 2026-10-08 | $9.07 | $8,909,494,156 | 17 / 20 |
| 2026-10-09 | $9.07 | $8,909,494,156 | 17 / 20 |
| 2026-10-10 | $9.07 | $8,909,494,156 | 17 / 20 |
| 2026-10-11 | $9.07 | $8,909,494,156 | 17 / 20 |
| 2026-10-12 | $9.07 | $8,909,494,156 | 17 / 20 |
| 2026-10-13 | $9.05 | $8,905,605,928 | 17 / 20 |
| 2026-10-14 | $9.05 | $8,905,605,928 | 17 / 20 |
| 2026-10-15 | $9.05 | $8,904,909,928 | 17 / 20 |
| 2026-10-16 | $9.05 | $8,904,909,928 | 17 / 20 |
| 2026-10-17 | $9.05 | $8,904,909,928 | 17 / 20 |
| 2026-10-18 | $9.05 | $8,904,906,175 | 16 / 19 |
| 2026-10-19 | $9.05 | $8,904,906,175 | 16 / 19 |
| 2026-10-20 | $9.05 | $8,904,906,175 | 16 / 19 |
| 2026-10-21 | $9.05 | $8,904,906,175 | 16 / 19 |
| 2026-10-22 | $9.06 | $8,904,906,175 | 16 / 19 |
| 2026-10-23 | $9.06 | $8,904,906,175 | 16 / 19 |
| 2026-10-24 | $9.06 | $8,904,906,175 | 16 / 19 |
| 2026-10-25 | $9.06 | $8,904,906,175 | 16 / 19 |
| 2026-10-26 | $9.06 | $8,904,906,175 | 16 / 19 |
| 2026-10-27 | $9.06 | $8,904,906,175 | 16 / 19 |
| 2026-10-28 | $9.06 | $8,904,906,175 | 16 / 19 |
| 2026-10-29 | $9.06 | $8,904,906,175 | 17 / 19 |
| 2026-10-30 | $9.06 | $8,904,906,175 | 17 / 19 |
| 2026-10-31 | $9.06 | $8,904,906,175 | 17 / 19 |
| 2026-11-01 | $9.06 | $8,904,906,175 | 17 / 19 |
| 2026-11-02 | $9.06 | $8,904,906,175 | 17 / 19 |
| 2026-11-03 | $9.06 | $8,904,897,842 | 17 / 19 |
| 2026-11-04 | $9.06 | $8,904,897,842 | 17 / 19 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 8 Buy / Strong Buy · 19 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
0 raises · 0 cuts · 0 unchanged · 2 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.